Assertio Holdings Inc

Assertio's capital structure shows a market cap of $150.5 million with a price-to-book ratio of 1.6, indicating a moderate premium to its book value. The company holds $10.2 million in cash and equivalents but has $39.1 million in long-term debt, resulting in a debt-to-equity ratio of 0.42. Despite a current ratio of 1.7, the company's operating cash flow is negative at -$28.2 million, and free cash flow is -$0.37 million, signaling liquidity constraints. Profitability metrics are weak, with a net loss of $30.4 million and an operating loss of $29.7 million. Return on equity is -32.3%, and return on assets is -11.4%, both significantly below industry norms for pharmaceutical firms. Gross profit of $83.3 million represents 70% of revenue, but this is insufficient to offset operating costs. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and regulatory changes. No material revenue is attributed to international operations, suggesting a U.S.-centric business model. Outlook for the current fiscal year is negative, with a net loss expected to persist. No growth in revenue is projected for the next fiscal year, and the company is unlikely to achieve positive operating income in the near term. Historical revenue trends show a decline in performance, with no clear catalysts for reversal. Risk factors include liquidity constraints, with negative net cash after subtracting total debt. The company has a low dilution risk, but its operating cash flow and free cash flow are insufficient to support debt servicing or growth initiatives. No recent filings or transcripts indicate material changes in strategy or operations. Analyst sentiment is mixed, with a mean recommendation of 2.75 (1=strong buy, 5=strong sell) and a median price target of $23.00. The high price target of $45.00 is an outlier, while the low price target of $18.00 reflects pessimism about the company's near-term prospects.